Showing 2081-2090 of 8180 results for "".
VShape Facial Contouring by Alma Lasers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/vshape-facial-contouring-by-alma-lasers/19251/VShape is a non-invasive and pain-free treatment for facial contouring. Performed throughout the world using Alma Lasers Accent Ultra medical aesthetic technology. vShape: Bipolar RF TechnologySunscreen Labeling
https://practicaldermatology.com/topics/practice-management/sunscreen-labeling-/19370/Neal Bhatia, MD discusses the impact of new sunscreen labeling on patient education, as well as strategies for UV avoidance, and trends in therapeutic development.Electronic Health Records
https://practicaldermatology.com/topics/practice-management/electronic-health-records/19383/Dr. Kaufmann discusses EHRs, government incentives, and the importance of choosing a system that is right for each practice. He offers tips for residents and young physicians for choosing and using electronic health records.BodyJet Irrigation Liposuction
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/bodyjet_meyer-irrigation/19519/Demonstration of proper technique for water-assisted liposuction, including placement of cannula and fat extraction.A Guidelines-Based Recommendations Algorithm for Atopic Dermatitis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/a-guidelines-based-recommendations-algorithm-for-atopic-dermatitis/48781/Christopher Bunick, MD, FAAD, compares the four approved and recommended biologics and two approved oral JAK inhibitors for treating atopic dermatitis with oral corticosteroidsPsoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.Making Connections: Success in Your First Five Years
https://practicaldermatology.com/topics/practice-management/webinar-making-connections-success-in-your-first-five-years/19819/Experts share practical guidance to help dermatologists chart a course for success. Topics range from getting involved in clinical trials to finding opportunities for leadership. Learn how to gain confidence prescribing systemic agents, and explore opportunities in medical dermatology.Practical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 5
https://practicaldermatology.com/programs/practical-dermatology/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-5/32903/Host Neal Bhatia, MD, FAAD, and guests Jason E. Hawkes, MD, MS, FAAD, and Laura K. Ferris, MD, PhD, FAAD, discuss getting clinicians out of the mindset of using traditional IL-17 and IL-23 blockers for generalized pustular psoriasis, understanding that it is a chronic disease that needs a chronic trPDT in Action: New Options for Actinic Keratosis
https://practicaldermatology.com/series/pdt-in-practice/pdt-in-action-new-options-for-actinic-keratosis/20210/Dr. Joel L. Cohen, a board-certified dermatologist practicing in Denver, shares insights into the use of photodynamic therapy (PDT) in his practice and how PDT has impacted the options for the treatment of actinic keratosis.Skin Cancer Prevention–Present and Future
https://practicaldermatology.com/programs/practical-dermatology/skin-cancer-prevention-present-and-future/18193/A panel discussion led by Neal Bhatia, MD, reveals the efforts – large and small – being made by dermatologists Laura Ferris, MD, Vishal Patel, MD, and Todd Schlesinger, MD, to combat skin cancer in their clinics and in their communities.